{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-073322","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2024-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.551308+00:00","generated_at":"2026-06-01T04:24:46.716858+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Invivyd announces VYD222 shows neutralizing activity against KP.1.1 and KP.3 SARS-CoV-2 variants","bullets":["VYD222 demonstrated in vitro neutralization of KP.1.1 FLiRT and KP.3 variants in pseudovirus assays.","Epitope at VYD222 binding interface is 99.8% conserved among 2024 GISAID sequences.","Next candidate VYD2311 also shows continued in vitro neutralization against these dominant strains.","FLiRT variants account for >50% of circulating SARS-CoV-2 sequences as of June 8, 2024.","CDC predicts KP.3 will become the most dominant lineage nationally in the near term."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-073322","json":"https://secwatch.observer/filing/0000950170-24-073322.json","markdown":"https://secwatch.observer/filing/0000950170-24-073322.md","text":"https://secwatch.observer/filing/0000950170-24-073322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000095017024073322/0000950170-24-073322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000095017024073322/ivvd-20240614.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:24:46.716858+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}